Category Archives: Corporate Responsibility

The HCR Taxman Cometh

By Guest Blogger | Published: September 13, 2011
By Tom Norton As the country struggles with the current economic malaise, and the pharmaceutical industry enters into yet another difficult quarter of “trying to make the numbers,” one matter that I doubt many Rx execs are thinking about today is the HCR Taxman.  That’s too bad.  They probably should.  That’s because he’s coming for the [...]
Also posted in Advertising, Agency Insight, Biotech, Strategy, compliance | Comments closed

Does Pharma Have a Debt Crisis Strategy?

By William Looney and Ben Comer | Published: July 20, 2011
The Obama Administration’s proposed fiscal budget for 2012 suggested that all bets are off for biopharmaceutical revenue safeguards, but it never had a chance with Congress, as evidenced by a unanimous no-thank-you from the Senate in late May. But that was before debt ceiling talks and the alleged possibility of a default emerged as the [...]
Also posted in Europe, Global, Strategy, healthcare, leadership, pricing | Tagged , , , , , | 1 Comment

Doing More With Less: A Leadership Perspective

By Jennifer Ringler | Published: July 19, 2011
Steven Blum, Director of Health Economics at Forest Laboratories and one of Pharm Exec’s 2011 Emerging Pharma leaders, recently spoke with Associate Editor Jennifer Ringler on building leadership and team rapport in today’s lean organization.
Also posted in Agency Insight, leadership | Tagged , , , , , | 2 Comments

Supreme Court Ruling Makes Generics More Dangerous

By Ben Comer | Published: June 23, 2011
Today’s Supreme Court ruling on Pliva v. Mensing, which held that generic drug companies are not responsible for updating drug labels in light of new safety concerns, makes taking generic drugs a riskier proposition for consumers, Justice Sonia Sotomayor wrote in her dissenting opinion. Justices Stephen Breyer, Elena Kagan and Ruth Bader Ginsburg also dissented [...]
Also posted in Legal | Tagged , | 1 Comment

Bad Ad: One Year of Fear

By Ben Comer | Published: June 13, 2011
FDA’s Bad Ad program, launched in May of 2010, resulted in some 328 reports of potentially untruthful or misleading promotion, a handful of Warning Letters, and several Untitled Letters. But the single most effective tool in the Bad Ad program’s toolkit, according to Arnie Friede, principal at Arnold I. Friede & Associates, and a former associate [...]
Also posted in Advertising, FDA, Legal, Marketing, Regulatory, compliance | Tagged , , , | Leave a comment